Clinical Trial Search

Primary: Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug — 0.23; 0.07; 1.24 ng/mL — p=0.01

Primary: HsCRP — -1.1; 0.5; -1.3; -0.3 mg/L

Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049

Primary: Peak VO2 — 14.5; 12.9 ml/kg/min

Primary: Functional Outcome 6 Months After Injury, as Measured by the Processing Speed Index — 82.5; 82.5 Processing speed index standardized scor

Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants

Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL

Primary: Reactive Hyperemic Response After 3 Months of Growth Hormone — 21.077 ml/dl min — p=0.644

Primary: BOLD Signal Measured by Functional MRI Scan to Functional Connectivity Measured by fMRI

Primary: Phosphocreatine Recovery — 0.74 correlation coefficient — p=0.02

Primary: MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. — 0.112; 0.104; 0.119; 0.111 unitless

Primary: Mean Overnight Growth Hormone — 1.2 mcg/L — p=<0.005

Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2

Primary: Change in Visceral Adipose Tissue Volume — -16; 19 cm2

Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale

Primary: Change in Insulin Sensitivity — 0.20; 1.44; -0.63; 0.14 uU*10^-4*min*ml^-1

Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min

Primary: PP1- Serum IGF-1 Levels, DXA, Resting Metabolic Rate, Total Body Water, 3-D Echo, Cardiac MRI, Dobutamine Stress Echocardiogram, Ergometry, General Health Assessment…

Primary: Height Standard Deviation Score — -2.52; -1.57; -1.19; -1.09 standard deviation score

Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants

Primary: Crohn's Disease Histologic Index of Severity (CDHIS) — 7; 8; 6; 8 scores on a scale

Primary: Mean Overnight Growth Hormone Levels — 0.85; 0.84 ng/mL — p=0.918

Primary: Change From Baseline of Growth Hormone — 1.15; -0.48 nanograms/ml — p=0.01

Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70

Primary: Body Composition — 51.2; 48.5; 52.1 percentage of body fat — p=<0.05

Primary: Aim 1: Stimulated Peak Growth Hormone Level — 5.2; 3.1; 1.9; 2.0 ng/ml

Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05

Primary: Percent Change of Triiodthyronine Over Baseline — -3.3; -6.1 percent change

Primary: Bone Metabolism — 34.3; 10.4 ng/ml

Primary: Liver Fat — -2.0; 0.9 Change in hepatic lipid-to-water %